|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||285.80 - 290.20|
|52 Week Range||120.60 - 290.20|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||103.83|
|Earnings Date||Oct 20, 2020|
|Forward Dividend & Yield||0.68 (0.23%)|
|Ex-Dividend Date||Jun 29, 2020|
|1y Target Est||107.60|
Based on dynamic business performance in the first six months of 2020 and on expectations that demand will remain high for the rest of the year, Sartorius Stedim Biotech, a leading partner of the biopharma industry, raised its growth and earnings forecast for fiscal 2020.
At the virtual combined Annual General Shareholders' Meeting (ASM) of Sartorius Stedim Biotech S.A., shareholders passed the resolution to pay a dividend of €0.34 per share for fiscal 2019. The previous year's dividend was €0.57 per share. The total profit distributed will be €31.3 million after €52.5 million in the previous year.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...